Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Recent & Breaking News (TSX:APLI)

Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt

GlobeNewswire August 21, 2024

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025

GlobeNewswire August 13, 2024

Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition

Business Wire July 25, 2024

Appili Therapeutics Announces Second Amendment to Arrangement Agreement

GlobeNewswire July 18, 2024

Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan

GlobeNewswire July 2, 2024

Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results

GlobeNewswire June 25, 2024

Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.

GlobeNewswire April 26, 2024

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Business Wire April 2, 2024

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

GlobeNewswire April 2, 2024

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

GlobeNewswire March 12, 2024

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

GlobeNewswire February 13, 2024

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Business Wire December 15, 2023

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

Business Wire November 13, 2023

Appili Therapeutics' Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

Business Wire October 25, 2023

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

Business Wire September 27, 2023

Appili Therapeutics Presents at the 10th International Tularemia Conference

Business Wire September 27, 2023

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral Suspension

Business Wire September 25, 2023

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Business Wire August 11, 2023

Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.

Business Wire June 29, 2023

Appili Therapeutics - Press Release Correction

Business Wire June 23, 2023